Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aspen Holdings Sells Asia‑Pacific Business to BGH Capital for AUD 2.37 Billion

Fineline Cube Jan 4, 2026
Company Deals Drug

China Approves Record 76 Innovative Drugs in 2025 as Out‑Licensing Hits $130 Billion

Fineline Cube Jan 4, 2026
Company Deals

Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform

Fineline Cube Jan 4, 2026
Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Fineline Cube Dec 31, 2025
Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Fineline Cube Dec 31, 2025
Policy / Regulatory

NHC Releases Fourth Batch Generic Drugs Catalogue, Prioritizing Innovation and Fertility Support

Fineline Cube Jan 4, 2026
Company Deals Drug

China Approves Record 76 Innovative Drugs in 2025 as Out‑Licensing Hits $130 Billion

Fineline Cube Jan 4, 2026
Company Drug

China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity

Fineline Cube Jan 4, 2026
Policy / Regulatory

China’s NRDL Update: New Drugs Available for Online Procurement

Fineline Cube Feb 15, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) drug procurement platform has released a notice stating that...

Company Medical Device

Mindray Launches First Wireless Handheld Ultrasound System, TE Air

Fineline Cube Feb 15, 2023

China-based medical device firm Mindray (SHE: 300760) has announced the market launch of the firm’s...

Company Deals

Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development

Fineline Cube Feb 14, 2023

Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China,...

Company Drug

Kangtai Biological Begins Phase I Trial for Tetravalent Influenza Vaccine

Fineline Cube Feb 14, 2023

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the first subject enrollment...

Company Drug

Jiangsu Recbio Completes First Tranche Enrollment for Shingles Vaccine REC610

Fineline Cube Feb 14, 2023

China-based Jiangsu Recbio Technology Co., Ltd has announced the completion of the first tranche of...

Company Drug

Beijing Wantai Initiates Phase I Study for 20-Valent Pneumonia Vaccine

Fineline Cube Feb 14, 2023

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has announced the initiation and...

Company Drug

Gracell Biotechnologies Gains IND Approval for GC012F in China

Fineline Cube Feb 14, 2023

Gracell Biotechnologies has reported receiving Investigational New Drug (IND) approval from the Center for Drug...

Hospital Policy / Regulatory

China’s Ministries Release Plan for Urban Medical Group Pilots

Fineline Cube Feb 14, 2023

A group of ministries led by the National Health Commission (NHC), including the National Development...

Company Deals Digital

ThinmedTech Partners with West China Hospital for CKD Digital Therapy

Fineline Cube Feb 14, 2023

ThinmedTech, a chronic disease clinical management solution provider based in Chongqing, has struck a partnership...

Company Drug

RemeGen Gains NMPA Approval for RC48 and Pyrotinib Clinical Study

Fineline Cube Feb 14, 2023

China-based RemeGen Ltd (HKG: 9995) has announced receiving the go-ahead from the National Medical Products...

Company Drug

Clover Biopharmaceuticals Administers First Dose of COVID-19 Vaccine SCB-2019 in Zhejiang

Fineline Cube Feb 14, 2023

China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced the first jab of its COVID-19 vaccine...

Company Deals

Hengrui Pharmaceuticals Licenses SHR2554 to Treeline Biosciences

Fineline Cube Feb 13, 2023

China’s Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced a licensing agreement with US-based Treeline Biosciences,...

Company Deals Drug

CSPC Pharmaceutical Licenses ADC SYS6002 to Corbus Pharmaceuticals

Fineline Cube Feb 13, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced a licensing agreement with Massachusetts-based Corbus...

Company Deals

Mingche Biotechnology Secures Pre-Series A Funding for Medical Device Innovation

Fineline Cube Feb 13, 2023

China-based high-value medical device firm Mingche Biotechnology (Suzhou) Co., Ltd has reportedly raised “tens of...

Company Deals

Dessight Biomedical Secures Pre-Series A Funding for Ophthalmic Innovations

Fineline Cube Feb 13, 2023

Hangzhou Dessight Biomedical has reportedly raised “tens of millions” of renminbi in a Pre-Series A...

Company Drug

Luye Pharma Initiates Phase I Study for BA1106, a CD25 Monoclonal Antibody

Fineline Cube Feb 13, 2023

China-based Luye Pharma Group (HKG: 2186) has announced the first subject dosing in a Phase...

Company Drug

Zelgen’s ZGGS15 Accepted for NMPA Review as First Global BsAb Filing

Fineline Cube Feb 13, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that a clinical trial filing for...

Company Drug

Kintor’s GT20029 Shows Positive Results in US Phase I Study for AGA and Acne

Fineline Cube Feb 13, 2023

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced positive topline data from a Phase I...

Company Drug

Hengrui’s HER2-Targeted ADC SHR-A1811 Aims for Breakthrough Designation

Fineline Cube Feb 13, 2023

China’s Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced that its SHR-A1811, an HER2 targeted antibody-drug...

Company Drug

EOC Pharma’s CDK7 Inhibitor EOC237 Accepted for CDE Review

Fineline Cube Feb 13, 2023

EOC Pharma, a biotech operating out of the US and China, has announced that a...

Posts pagination

1 … 501 502 503 … 603

Recent updates

  • Aspen Holdings Sells Asia‑Pacific Business to BGH Capital for AUD 2.37 Billion
  • China Approves Record 76 Innovative Drugs in 2025 as Out‑Licensing Hits $130 Billion
  • China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity
  • Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform
  • Genmab Discontinues Acasunlimab to Focus on Late‑Stage Portfolio
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aspen Holdings Sells Asia‑Pacific Business to BGH Capital for AUD 2.37 Billion

Company Deals Drug

China Approves Record 76 Innovative Drugs in 2025 as Out‑Licensing Hits $130 Billion

Company Drug

China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity

Company Deals

Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.